LitCovid-sentences  

PMC:7321036 / 45571-47325 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T300 0-87 Sentence denotes Figure 7 Mapping Regulated Kinases to Kinase Inhibitors Identifies SARS-CoV-2 Therapies
T301 88-196 Sentence denotes (A) Kinase inhibitors (left) mapped to kinases (right) whose activity was regulated by SARS-CoV-2 infection.
T302 197-272 Sentence denotes Lines connecting them indicate known kinase targets for each drug/compound.
T303 273-385 Sentence denotes (B) Vero E6 cells pre-treated with remdesivir at the indicated doses, followed by SARS-CoV-2 infection for 48 h.
T304 386-524 Sentence denotes Percent viral titer compared with mock drug treatment (anti-NP antibody; red line, dots, and text) and cell viability (black) is depicted.
T305 525-549 Sentence denotes Error bars represent SD.
T306 550-564 Sentence denotes (C) As in (B).
T307 565-629 Sentence denotes Vero E6 cells were treated with the CK2 inhibitor silmitasertib.
T308 630-763 Sentence denotes Physical interactions between N protein and the CSNK2A2 and CSNK2B CK2 subunits were observed in a prior study (Gordon et al., 2020).
T309 764-957 Sentence denotes (D) Predicted increased kinase activity for the p38 signaling pathway and drugs/compounds targeting pathway members (ralimetinib, MAPK13-IN-1, and ARRY-797) and upstream drivers (gilteritinib).
T310 958-974 Sentence denotes (E–G) As in (B).
T311 975-1149 Sentence denotes Vero E6 cells treated with the AXL inhibitor gilteritinib (E), the MAPK11/14 inhibitor ralimetinib (F), or the MAPK13 inhibitor MAPK13-IN-1 (G) prior to SARS-CoV-2 infection.
T312 1150-1264 Sentence denotes (H) A549-ACE2 lung epithelial cells were treated with the MAPK14 inhibitor ARRY-797 prior to SARS-CoV-2 infection.
T313 1265-1489 Sentence denotes (I) Small interfering RNA (siRNA) knockdown of p38 pathway genes in A549-ACE2 leads to a significant decrease in SARS-CoV-2 viral replication (red), as assessed by qRT-PCR in the absence of effects on cell viability (black).
T314 1490-1581 Sentence denotes ACE2 and non-targeting siRNAs are included as positive and negative controls, respectively.
T315 1582-1734 Sentence denotes (J and K) Vero E6 or A549-ACE2 cells were treated with PIKFYVE inhibitor apilimod (J) or the CDK inhibitor dinaciclib (K) prior to SARS-CoV-2 infection.
T316 1735-1754 Sentence denotes See also Figure S6.